Pepgen reports fourth quarter and full year 2023 financial results and recent corporate developments

- enrollment completed for pgn-edo51 5 mg/kg cohort in connect1-edo51 phase 2 clinical trial in dmd patients. the company expects to announce preliminary data from the 5 mg/kg dose cohort in mid-2024 –
PEPG Ratings Summary
PEPG Quant Ranking